Close Menu

Mammoth Biosciences

The tests are designed to detect viral RNA in individual respiratory specimens, while BayCare's tests can be used with pooled samples.

The CRISPR-COVID assay, which is the first CRISPR-based test for SARS-CoV-2 in China, is faster than PCR-based testing, the researchers said.

The company has taken an exclusive license to the Casɸ proteins and is working to characterize their capabilities to determine how they can best be used.

The seven technologies feature different methods, including CRISPR and microfluidics, and can be performed in many settings and with a variety of sample types.

Caspr's assay can be transported at room temperature and performed without complex external equipment, making it ideal for low-resource environments.

UCSF's test, developed with Mammoth Biosciences, uses CRISPR technology, while the tests from the Broad Institute and BioSewoom are PCR-based.

The companies will combine the Binx io diagnostic platform with Sherlock Bio's CRISPR technology to create an easy-to-use rapid test for the point of care.

In a study published last month, Mammoth demonstrated the technology's sensitivity, specificity, and speed compared to PCR-based COVID-19 testing.

The researchers said their assay can be run in 30 to 45 minutes, with 95 percent positive predictive agreement and 100 percent negative predictive agreement.

The company recently inked deals with Mammoth Biosciences and Rutgers University to license a protein discovery platform and gene editing technology.

Pages

President Donald Trump might not approve the stricter standards the US Food and Drug Administration is developing for authorizing a SARS-CoV-2 vaccine, according to Politico.

Wired reports that Oxitec has now developed a genetically modified fall armyworm.

A large genetic study finds SARS-CoV-2 viruses with a certain variant are spreading more than others, according to the Washington Post.

In Nature this week: sister-chromatid-sensitive chromosome conformation capture approach, and more.